How empagliflozin may help aging arteries
Treatments studied
Part of Heart & circulation clinical trials.
This study tests if a diabetes medication, empagliflozin, can reduce age-related stiffening of arteries in people without diabetes. If you are between 60 and 80 and have stiff arteries, this trial could help improve your vascular health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 80 years old (if female, you must have had no periods for over a year).
- Your blood pressure medicine has been the same for at least 3 months (if you take any).
- You have stiff arteries, confirmed by a simple test during a screening visit.
- You do not have diabetes, a history of heart disease, or certain other conditions (see exclusions).
- You are not regularly exercising more than 3 days a week at a moderate or intense level.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an SGLT2 inhibitor (a type of diabetes medication) can help reduce stiffness in the arteries of veterans who have obesity. If you are a veteran aged 30-60 with a BMI of 30-45 and have stiffer arteries than expected for your age, this study might be an option.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This study tests a diabetes medication called empagliflozin to see if it helps improve the health of blood vessels in people with slightly elevated blood pressure. It may help protect blood vessels from damage that can lead to heart problems later.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Hear when a new Arterial Stiffness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.